

08 Dec 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/taiho-oncology-presents-data-on-all-oral-regimens-azacitidine-and-cedazuridine-and-decitabine-and-cedazuridine-at-the-2025-american-society-of-hematology-annual-meeting-and-exposition-302634528.html

09 Jul 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/taiho-oncology-and-taiho-pharmaceutical-announce-us-fda-acceptance-of-supplemental-new-drug-application-for-inqovi-in-combination-with-venetoclax-to-treat-patients-with-acute-myeloid-leukemia-302501545.html

14 Jan 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/taiho-oncology-announces-decitabine-and-cedazuridine-to-be-included-in-nih-precision-medicine-trials-302350281.html

05 Nov 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/taiho-oncology-to-present-data-at-the-66th-american-society-of-hematology-annual-meeting-302296677.html

23 Jan 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/taiho-oncology-announces-publication-of-final-results-of-the-phase-3-ascertain-clinical-trial-of-oral-decitabine-and-cedazuridine-fixed-dose-combination-inqovi-in-patients-with-mds-and-cmml-302041085.html

10 Dec 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/taiho-oncology-announces-presentation-of-data-from-a-us-real-word-study-of-oral-decitabine-and-cedazuridine-302010317.html